Press Releases

WALTHAM, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Pain Society (APS) Annual Scientific Meeting to be held in Anaheim, CA, March 4-6.

The study leveraged the Quell® Health Cloud, which connects with the Quell wearable pain relief device and its companion smartphone app. The cloud database stores the user's demographic and clinical profile, health metrics including pain, sleep, activity and gait, and device utilization. The Quell Health Cloud has over fifty thousand registered Quell users and is rapidly becoming one of the largest chronic pain databases in the world. The scientific poster is titled "Dose-Response of Surface Neurostimulation in Chronic Pain.”

"Chronic pain is a complex biopsychosocial condition that requires a customized treatment approach. Our vision is to leverage the unique data assets we are collecting in the Quell Health Cloud to deliver personalized pain relief for our customers," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We are particularly interested in how therapeutic dose impacts Quell effectiveness. The data that will be presented at APS was from over 4000 Quell users and shows that daily use yields the greatest improvement in pain intensity and pain interference with function. We are in the process of translating these findings into actionable directions for Quell users.”

About Quell

Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through select retailers. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.